RTTNews | Apr 13, 2021 07:19AM EDT

07:18 Tuesday, April 13, 2021 (RTTNews.com) - Biotechnology company Rigel Pharmaceuticals, Inc. (RIGL) announced Tuesday positive topline results from a multi-center, Phase 2 clinical trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized patients with COVID-19.

The trial, being conducted in collaboration with the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), and Inova Health System, met its primary endpoint of safety. Fostamatinib reduced the incidence of Serious Adverse Events (SAEs) by half.

Based on these data, Rigel plans to discuss the potential for emergency use authorization (EUA) with the U.S. Food and Drug Administration (FDA) of fostamatinib as a treatment for hospitalized patients with COVID-19.

Read the original article on RTTNews ( https://www.rttnews.com/3184483/rigel-pharma-says-phase-2-trial-of-fostamatinib-for-covid-19-met-primary-endpoint-of-safety.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved